Follow
Clio P. Mavragani
Title
Cited by
Cited by
Year
Sjögren’s syndrome
CP Mavragani, GE Fragoulis, HM Moutsopoulos
The Autoimmune Diseases, 495-510, 2014
4812014
The geoepidemiology of Sjögren's syndrome
CP Mavragani, HM Moutsopoulos
Autoimmunity reviews 9 (5), A305-A310, 2010
4062010
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
M Dastmalchi, C Grundtman, H Alexanderson, CP Mavragani, ...
Annals of the rheumatic diseases 67 (12), 1670-1677, 2008
2912008
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis
A Nezos, F Gravani, A Tassidou, EK Kapsogeorgou, M Voulgarelis, ...
Journal of autoimmunity 63, 47-58, 2015
2602015
Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use
S Fragkioudaki, CP Mavragani, HM Moutsopoulos
Medicine 95 (25), e3766, 2016
2382016
Cardiovascular disease in systemic lupus erythematosus: a comprehensive update
M Giannelou, CP Mavragani
Journal of autoimmunity 82, 1-12, 2017
1912017
Activation of the type I interferon pathway in primary Sjogren’s syndrome
CP Mavragani, MK Crow
Journal of autoimmunity 35 (3), 225-231, 2010
1862010
Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanercept
CP Mavragani, TB Niewold, NM Moutsopoulos, SR Pillemer, SM Wahl, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2007
1862007
Central nervous system involvement in Sjögren’s syndrome
FC Soliotis, CP Mavragani, HM Moutsopoulos
Annals of the rheumatic diseases 63 (6), 616-620, 2004
1702004
Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease
CP Mavragani, I Sagalovskiy, Q Guo, A Nezos, EK Kapsogeorgou, P Lu, ...
Arthritis & rheumatology 68 (11), 2686-2696, 2016
1682016
The management of Sjögren's syndrome
CP Mavragani, NM Moutsopoulos, HM Moutsopoulos
Nature clinical practice Rheumatology 2 (5), 252-261, 2006
1662006
Sjögren's syndrome: old and new therapeutic targets
CP Mavragani, HM Moutsopoulos
Journal of autoimmunity 110, 102364, 2020
1412020
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
A Nezos, A Papageorgiou, G Fragoulis, D Ioakeimidis, M Koutsilieris, ...
Journal of autoimmunity 51, 89-98, 2014
1312014
Predicting the outcome of Sjogren’s syndrome-associated non-hodgkin’s lymphoma patients
A Papageorgiou, DC Ziogas, CP Mavragani, E Zintzaras, AG Tzioufas, ...
PloS one 10 (2), e0116189, 2015
1232015
Conventional therapy of Sjogren’s syndrome
CP Mavragani, HM Moutsopoulos
Clinical reviews in allergy & immunology 32, 284-291, 2007
1072007
Endocrine alterations in primary Sjogren's syndrome: an overview
CP Mavragani, GE Fragoulis, HM Moutsopoulos
Journal of autoimmunity 39 (4), 354-358, 2012
1052012
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon‐β/α ratios in rheumatoid arthritis patients: a post hoc …
CP Mavragani, DT La, W Stohl, MK Crow
Arthritis & Rheumatism: Official Journal of the American College of …, 2010
1022010
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations
F Gravani, I Papadaki, E Antypa, A Nezos, K Masselou, D Ioakeimidis, ...
Arthritis research & therapy 17, 1-13, 2015
1002015
Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study
D Karaiskos, CP Mavragani, S Makaroni, E Zinzaras, M Voulgarelis, ...
Annals of the rheumatic diseases 68 (1), 40-46, 2009
952009
Mechanisms and new strategies for primary Sjögren's syndrome
CP Mavragani
Annual Review of Medicine 68 (1), 331-343, 2017
932017
The system can't perform the operation now. Try again later.
Articles 1–20